MICHAEL C. BACH, M.D.; SANDRA P. BAGWELL, M.D.; NANCY P. KNAPP, M.D.; KENT M. DAVIS, M.D.; PETER S. HEDSTROM, M.D.
Disseminated cytomegalovirus infection is a major cause of mortality in patients with the acquired immuno-deficiency syndrome (1) as well as in other immunosuppressed patients including bone marrow transplant recipients (2). We have had recent positive results with the use of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), a new nucleoside antiviral agent, in halting progressive hemorrhagic retinitis and symptomatic pneumonitis due to cytomegalovirus. We report our experience with DHPG in three patients with the acquired immunodeficiency syndrome.
Patient 1: A 31-year-old man was diagnosed as having the acquired immunodeficiency syndrome in November 1983 when he developed Pneumocystis carinii pneumonia. In June 1984 he developed a
MICHAEL C. BACH, SANDRA P. BAGWELL, NANCY P. KNAPP, KENT M. DAVIS, PETER S. HEDSTROM. 9-(1,3-dihydroxy-2-propoxymethyl)guanine for Cytomegalovirus Infections in Patients with the Acquired Immunodeficiency Syndrome. Ann Intern Med. 1985;103:381–382. doi: 10.7326/0003-4819-103-3-381
Download citation file:
Published: Ann Intern Med. 1985;103(3):381-382.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use